NCT05879757

Real-world Usage of HyQvia in Multiple Myeloma Adults With Secondary Immunodeficiency

A Prospective, Observational Study to Assess the Real-World Usage and Outcomes of HyQvia in Patients With Multiple Myeloma (MM) Diagnosed With Secondary Immunodeficiency (SID)

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 75 (estimated)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

In this study, multiple myeloma participants with secondary immunodeficiency (SID) will be treated with HyQvia according to their clinic's standard practice. The study's main aim is to look into infusion parameters of HyQvia administration.

Detailed description

This is a prospective, observational study of adults having multiple myeloma (MM) with SID treated with HyQvia as part of routine clinical care. This study will characterize the real-world infusion parameters of HyQvia administration. The study will enroll approximately 100 participants. Study data will be requested through participants' routine clinic visits and patient-reported outcome (PRO)s are voluntary. This multi-center trial will be conducted in selected European and South American countries. The overall time of this study is 38 months. Participants will make multiple visits to the clinic within 12 months after enrolment for follow-up assessments.

Conditions

• Multiple Myeloma
• Secondary Immunodeficiency (SID)

Interventions

Type	Name	Description
OTHER	No Intervention	As this is an observational study, no intervention will be administered in this study.

Timeline

• Start date: 2023-10-17
• Primary completion: 2027-02-16
• Completion: 2027-02-16
• First posted: 2023-05-30
• Last updated: 2026-02-18

Locations

27 sites across 11 countries: Argentina, Czechia, France, Germany, Greece, Italy, Poland, Romania, Spain, Sweden, Turkey (Türkiye)